Background: Primary brain tumors (PBTs) include any tumor in the brain whose prognosis is weak because of their histological characteristics. Aim: Herein, this study aimed to assess the HER2 tumor marker frequency in PBTs. Materials and methods: This study was done on the samples of primary brain tumor diagnosis from 2008 to 2015. Results: Out of 107 patients of brain tumor that had a mean age of 40.4 years (61.7% men), the most common location of the tumor was in the supratentorial region (63.85% cases). The prevalence of high-grade astrocytoma (HGA) and lowgrade astrocytoma (LGA) at diagnosis was 43.9% and 37.4%, respectively. With regard to HER2 score, HER2-positive (scores 2 & 3) was in 42.1% of patients. On the other hand, HER2-negative (¡) was in 57.9%, 2þ in 33.6%, and 3þ in 8.4% of patients. The patients of LGA had significantly younger ages, lower HER2 positivity, and lower HER2 percent compared with the HGA patients. Conclusions: The type of brain tumors can impact on HER2 expression that high HER2 expression in HGA may be helpful for therapeutic aims. Further studies are required to support these results with a higher volume of patients in the world.

Background and objectives: Primary brain tumors include any tumors arising in the brain whose prognosis is poor due to their histologic characteristics. The aim of this research was to evaluate the frequency of HER2 tumor marker in primary malignant brain tumors. Materials and Methods: This descriptive study was conducted on the samples admitted to the pathology laboratory with diagnosis of primary brain tumor during 2008–2015. Results: From among 107 patients (61.7% males and the rest females) with mean age of 40.4 years, the highest frequency of tumor location was in supratentorial region of the brain (including lobes and ventricles) (63.85% cases). High-grade astrocytoma had the highest prevalence at diagnosis (43.9%), followed by low-grade astrocytoma (37.4%). As for HER2 score, 42.1% of patients were HER2-positive (scores 2 & 3). On the other hand, 5.6% of patients were HER2-negative (-), 40.2% were positive (+), and 54.2% were positive (++). The patients with high-grade astrocytoma had older age (P < 0.001), higher HER2 positivity (P = 0.024) and percentage (P < 0.001) compared to the patients with low-grade astrocytoma. Conclusions: HER2 expression is dependent on the type of brain tumors. High expression of HER2 in high-grade astrocytoma may be useful for therapeutic purposes. The future research is needed to confirm these results with a large number of patients in different areas.

Objective: Multifocality in gynecologic malignancies is a common phenomenon, however synchronous tumors may occur. Synchronous cancers are about 1.7% of gynecologic malignancies. Methods: A 57-year old female with chief complaint of vaginal bleeding was admitted. Endometrial curettage and cervical biopsy was done.Result: Pathologist reported: compatible with papillary adenocarcinoma, Grade II in endometrial sample and squamous epithelium with moderate dysplasia and tiny fragments of atypical glandular epithelium in endocervical samples. The patient refused for surgical excision of the lesion and insisted on to treat with conventional herbal medicine. Later Pap smear was done and pathologist reported: “High grade squamous intraepithelial lesion (HSIL) and atypical glandular cells, favor neoplastic in atrophic background”. Conclusion: In the case of gynecologic cancer be careful that it may accompany another gynecologic malignancy or premalignant lesion. The second lesion may occur synchronous or metachronous or may be metastatic. Many of the synchronous malignancies are presented in lower stages and have better prognosis than metastatic lesion. Thorough sampling and examination is important in correct diagnosis and treatment.